Mydecine Innovations Group Inc.

DB:0NF0 Stock Report

Market Cap: €225.2k

Mydecine Innovations Group Past Earnings Performance

Past criteria checks 0/6

Mydecine Innovations Group has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been declining at an average rate of 77.2% per year.

Key information

2.5%

Earnings growth rate

65.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-77.2%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mydecine Innovations Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0NF0 Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1242
31 Mar 240-1151
31 Dec 230-2181
30 Sep 230-19112
30 Jun 230-20122
31 Mar 230-21133
31 Dec 220-16124
30 Sep 220-23154
30 Jun 220-18164
31 Mar 220-24175
31 Dec 210-24184
30 Sep 210-19123
30 Jun 210-37143
31 Mar 210-32142
31 Dec 200-27101
30 Sep 200-3990
30 Jun 200-2350
31 Mar 200-2020
31 Dec 190-2130
30 Sep 190-550
30 Jun 190-550
31 Mar 190-1160
31 Dec 180-1360
30 Sep 180-22120
30 Jun 180-21110
31 Mar 180-18130
31 Dec 170-18150
30 Sep 170-14100
30 Jun 170-14100
31 Mar 170-1170
31 Dec 160-840
30 Sep 160-110
30 Jun 160-110
31 Mar 160-330
31 Dec 150-440
30 Sep 150-440
30 Jun 150-440
31 Mar 150-210
31 Dec 140-110
30 Sep 140-100
31 Mar 140000
31 Dec 130000

Quality Earnings: 0NF0 is currently unprofitable.

Growing Profit Margin: 0NF0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0NF0 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare 0NF0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0NF0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: 0NF0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies